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Objective: To investigate the intracellular and soluble cytokine levels and T cell subsets in peripheral blood
of patients with active and inactive polymyositis and dermatomyositis.
Methods: The frequencies of T and B lymphocytes, T helper (Th), and T cytotoxic (Tc) cells and of interferon
c (IFNc), interleukin (IL)4, and IL10 expression of CD4+ or CD8+ cells were determined by flow cytometry.
The concentrations of soluble cytokines were measured with commercial enzyme linked immunosorbent
assays.
Results: In active dermatomyositis there was a decreased percentage of T (CD3+) lymphocytes and Tc
(CD8+) lymphocytes, decreased IFNc expression of CD4+ and CD8+ cells, but an increase in B and IL4
producing CD4+ lymphocyte frequencies. These prominent changes disappeared in the inactive stage of
the disease. In polymyositis no significant change in these lymphocyte subsets or in intracellular cytokine
expression could be detected in either the active or the inactive form. The frequency of IL4+/IFNc+ Th cells
was calculated and a significantly increased Th2/Th1 frequency was found in active dermatomyositis, and
a decreased frequency in inactive dermatomyositis, compared with the control population.
Conclusions: There appears to be a difference between polymyositis and dermatomyositis in the level of
peripheral blood lymphocytes and their intracellular cytokine content. These findings provide further
evidence for a difference in the pathogenesis of polymyositis and dermatomyositis.
P
olymyositis and dermatomyositis are idiopathic inflam-
matory myopathies of unknown origin, although immu-
nological mechanisms may be involved in their
pathogenesis.1 2 There are data suggesting that these two
diseases may be pathogenically similar,3–7 while other reports
provide evidence that their origin essentially different.
In polymyositis T cell mediated cytotoxicity rather than
humoral immunity may be the main effector mechanism, as
immunohistochemical studies on muscle biopsies have
shown that most of the T cells in the endomysium
surrounding and invading single myofibres are of CD8+
type.1 8 9 Cytotoxic granules of CD8+ T cells release perforin
and serine esterases, which contribute to muscle cell death.
Oligoclonal expansions of CD8+ T cells have been found in
the blood and within muscle biopsies in polymyositis, but not
in dermatomyositis.10–12 On the other hand in dermatomyo-
sitis humorally mediated damage to muscle blood vessels
seems to be more important in the pathogenesis.
Inflammatory infiltrates mainly consist of activated B cells
and are concentrated in the interstitial and perivascular
areas.13 14 Deposition of the membrane attack complex of
complement is often seen in the muscle vessels in dermato-
myositis, and the vessel injury appears to be complement
mediated.15 The pattern of perifascicular atrophy of muscle
fibres is characteristic and attributed to ischaemic effects.
Cytokines have important functions in inflammatory
processes and are likely to participate in the pathogenesis
of idiopathic inflammatory myopathies. The role of cytokines
in these diseases is, however, poorly understood. Cytokine
studies have shown raised serum interleukin 1 (IL1) receptor
antagonist in patients with active polymyositis and derma-
tomyositis, but low levels of tumour necrosis factor a and
IL1b.16 Immunohistochemical investigations of cytokines
showed that cytokine expression in muscle tissue is
dominated by IL1a, IL1b, and transforming growth factor
(TGF)b1–3.17 Local release of T cell derived cytokines is not
remarkable in inflammatory myopathies. To detect the
cytokine secretion of peripheral blood mononuclear cells
the ELIspot assay was used previously in one study, but no
published data are available on intracellular cytokine
production measured by flow cytometry in polymyositis and
dermatomyositis.9
To gain better insight into the pathogenesis of these
myopathies we investigated cytokine levels in the sera of
patients with polymyositis and dermatomyositis. We also
used a flow cytometric assay to detect the peripheral blood
lymphocyte subsets and the intracellular cytokines produced
in these cells. An additional aim was to investigate the
proportion of T helper (Th) 1 (CD4+/IFNc+), Th2 (CD4+/
IL4+), T cytotoxic (Tc) 1 (CD8+/IFNc+), and Tc2 (CD8+/IL4+)
lymphocytes in polymyositis and dermatomyositis. Patients
were tested in both the active and the inactive states of the
disease.
METHODS
Patients and controls
Individuals enrolled in this study were patients suffering
from polymyositis (37 women, 13 men; mean (SD) age 45.9
(13.7) years, range 20 to 69) or dermatomyositis (33 women,
16 men; age 46.9 (13.5) years, range 13 to 73) followed up in
our outpatient department. Their diagnosis was defined on
the basis of the international criteria of Boham and Peter18
and the disease activity assessment was based on the clinical
symptoms, muscle strength, and laboratory indices (serum
creatinine kinase (CK) and lactate dehydrogenase (LDH)
activity, table 1). The number of patients with active
polymyositis was 13 (eight women, five men; mean (SD)
age, 43.1 (14.1) years), while 37 patients were in the inactive
stage of the disease (29 women, eight men; age 46.9 (13.6)
years) at the initiation of the study. The number of patients
with active dermatomyositis was 29 (18 women, 11 men; age
1485
www.annrheumdis.com
46.5 (13.5) years), while 20 (15 women, five men; age 47.4
(13.6) years) had inactive disease. The healthy controls were
members of the clinical staff (24 women, eight men; age 30.9
(9.1) years, range 20 to 56). Informed consent was obtained
from each control and patient.
Phenotypic characterisation of whole blood
lymphocytes
Heparinised whole blood was incubated in the presence of
saturating concentrations of directly labelled monoclonal
antibodies (mAb) for 30 minutes at room temperature in the
dark. The erythrocytes were lysed and the samples were fixed
according to the Coulter QPREP protocol (Coulter, Hialeah,
Florida, USA). The monoclonal antibodies applied were: FITC
labelled anti-CD3 and FITC labelled CD8 (Sigma, St Louis,
Missouri, USA); PE labelled anti-CD4, PerCP labelled anti-
CD19, and FITC labelled anti-CD3/PE labelled anti-HLA-DR
(Immunotech, Nyon, Switzerland); and CyChrome labelled
anti-CD69 (Pharmingen, BD Biosciences, San Jose,
California, USA). The samples were measured using a
Coulter EPICS XL flow cytometer and analysed by System
II 3.0 software. Lymphocytes were gated on their forward and
side scatter properties and the proportions of B cells, Th cells,
Tc cells, and resting and activated T cells were determined
within the defined lymphocyte gate, based on their antigen
positivity.
Measurement of intracellular cytokine expression of
Th and Tc lymphocytes in whole blood
As resting lymphocytes do not contain substantial quantities
of cytokines, we stimulated T cells in whole blood by
phorbole myristate acetate (PMA, 25 ng/ml, Sigma) and
ionomycin (1 mg/ml, Sigma) for four hours at 37 C˚. Activation
was done in the presence of Brefeldin-A (Sigma, 10 mg/ml)
which inhibits intracellular transport so that cytokines
produced during the activation will be retained inside the
cells. After the stimulation of the Th and Tc cells, samples
were marked by quantum red labelled anti-CD4 or anti-CD8
(Sigma) mAb for 30 minutes at room temperature in the
dark. Then FACS lysing solution (Becton Dickinson, San
Jose, California, USA) was used for 10 minutes to lyse the
erythrocytes and fix the whole blood leucocytes. After a
washing step, the plasma membrane of the cells was
permeabilised by the FACS permeabilising solution (Becton
Dickinson) for another 10 minutes. The fixed and permea-
bilised leucocytes were labelled by anti-IFNc-FITC and anti-
IL4-PE (Becton Dickinson) or anti-IL10-PE mAb (Caltag,
Burlingame, California, USA) for 30 minutes at room
temperature in the dark. The samples were measured by a
Coulter EPICS XL flow cytometer. Data from about 5000 Th
or Tc lymphocytes were collected in each sample. These cells
were gated, based on their side scatter/forward scatter and
CD4 or CD8 positivity. The proportion of IFNc, IL4, and IL10
positive cells was determined among the CD4+ and CD8+ T
cells.
Measurement of autoantibodies
Anti-ENA and anti-Jo-1 (Hycor) antibodies were detected by
enzyme linked immunosorbent assay kits (ELISA). We
detected antinuclear factor (ANF) antibodies in HEp-2 cells
by an indirect immunofluorescence technique.
Measurement of serum cytokine concentrations by
ELISA
We measured the levels of circulating cytokines (IFNc, IL4,
and IL10) in the serum of patients and controls. Serum
samples were collected on every experimental day and were
stored at –80 C˚ until testing with commercial cytokine
ELISAs (OptEIATM system, Pharmingen) according to the
manufacturer’s instructions.
Statistical analysis
The differences between the healthy controls and the patients
with polymyositis or dermatomyositis were calculated by
Student’s unpaired t test. Correlations between variables
were assessed by Pearson regression using the Statistica for
Table 1 Autoantibody positivities in active and inactive
polymyositis (aPM and iPM) and dermatomyositis (aDM
and iDM)
Active disease
Inactive
disease p Value
Dermatomyositis
n 29 20
Age (years) 46.5 (13.5) 47.4 (13.6) NS
Age range (years) 13 to 70 24 to 73
Male/female 11/18 5/15
CK (U/l) 1371 (2254) 74 (35) p=0.01
LDH (U/l) 764 (527) 362 (84) p,0.01
Anti-ENA positivity 4 2 NS
Anti-Jo-1 positivity 1 0 NS
ANF HEp-2 positivity 4 9 NS
Polymyositis
n 13 37
Age (years) 43.1 (14.1) 46.9 (13.6) NS
Age range (years) 20 to 69 18–69
Male/female 5/8 8/29
CK 1000 (1873) 169 (235) p=0.01
LDH 1028 (1430) 394 (143) p=0.01
Anti-ENA positivity 5 4 p=0.03
Anti-Jo-1 positivity 4 2 p=0.01
ANF HEp-2 positivity 3 4 NS
Values are mean (SD) or n unless specified. Significant p values in bold.
ANF, antinuclear factor; CK, creatine kinase; ENA, extractable nuclear
antigen; LDH, lactate dehydrogenase.
Table 2 T cell subpopulations and activated T cells in peripheral blood in controls and in patients with active and inactive
dermatomyositis
Patients with aDM
(n = 29)
Patients with iDM
(n = 20) Controls (n = 32)
p Values
aDM v control iDM v control aDM v iDM
CD3+ cells (%) 64.8 (11.4) 71.8 (7.1) 70.3 (7.2) p,0.01 NS p,0.05
CD4+ cells(%) 48.3 (10.1) 49.2 (10.9) 45.2 (7.6) NS NS NS
CD8+ cells (%) 15.1 (7.1) 20.9 (9.3) 19.6 (5.9) p,0.01 NS p,0.05
CD19+ cells (%) 16.8 (10.7) 11.1 (4.3) 11.7 (4.1) p,0.01 NS p,0.05
CD3+ and HLADR+ cells (%) 6.4 (4.1) 7.4 (5.7) 3.0 (2.3) p,0.01 p,0.01 NS
CD3+ and CD69+ cells (%) 1.4 (0.9) 1.3 (0.7) 1.0 (0.8) NS NS NS
Values are mean (SD). Significant p values in bold.
The samples were measured by flow cytometry and lymphocytes were identified on the basis of their scatter properties.
aDM, active dermatomyositis; iDM, inactive dermatomyositis.
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Windows software. A significant difference was defined as
p(0.05.
RESULTS
Distribution of lymphocyte subpopulations in whole
blood of patients suffering from active or inactive
dermatomyositis or polymyositis
We found a major difference in lymphocyte phenotypisation
only in the case of dermatomyositis. Patients in the active
state of this disorder had a significantly decreased percentage
of CD3+ cells (p,0.01) and CD8+ cells (p,0.01), and an
increased percentage of CD19+ cells (p,0.01) compared with
healthy controls and with the inactive disease state (table 2).
Beside the regular lymphocyte subtypes we also deter-
mined the percentage of activated T cells in our samples
based on the HLA-DR or CD69 expression of CD3 positive
T cells. Independent of the activity of the disorders we
observed significantly increased frequencies only in the
CD3+/HLA2 DR+ cells both in dermatomyositis and poly-
myositis compared with the controls (control v active
dermatomyositis, p,0.01; v inactive dermatomyositis,
p,0.01; v active polymyositis, p,0.01; v inactive polymyosi-
tis, p,0.01; tables 2 and 3).
Intracellular cytokine expression in peripheral
lymphocytes of patients with dermatomyositis
The frequency of IFNc+ Th1 cells was significantly lower
(p,0.01) in active dermatomyositis than in controls or in
patients with inactive disease (active disease, 10.6 (7.1)%;
inactive disease, 22.7 (10.0); control, 22.1 (10.0)%). The
frequency of IFNc+ Tc1 lymphocytes was also significantly
decreased in active dermatomyositis compared with the
controls (active disease, 24.4 (16.5)% v 43.4 (8.5)% in
controls, p,0.01) (fig 1A).
The percentage of IL4+ Th2 cells was markedly increased in
active dermatomyositis and decreased in inactive dermato-
myositis compared with the controls (active disease, 1.01
(0.66)%; inactive disease, 0.33 (0.3)%; controls, 0.62
(0.54)%), and the difference between the values of the active
and inactive states was significant (p=0.05) (fig 1B). In
CD8+ cells we could not detect any measurable change in
intracellular IL4 expression.
The frequencies of IL10-containing CD4+ and CD8+ T cells
were higher in both active and inactive dermatomyositis, but
the differences were significant only for inactive dermato-
myositis (CD4+/IL10+: control, 2.8 (4.1)%; inactive dermato-
myositis, 6.5 (5.6)%, p=0.04; CD8+/IL10+: control, 3.7
(4.3)%, inactive disease, 8.8 (6.7)%, p=0.01).
Table 3 T cell subpopulations and activated T cells of peripheral blood in controls and in patients with active and inactive
polymyositis
p Values
Patients with aPM
(n = 13)
Patients with iPM
(n = 37) Controls (n = 32) aPM v control iPM v control aPM v iPM
CD3+ cells (%) 66.2 (9.4) 70.4 (8.1) 70.3 (7.2) NS NS NS
CD4+ cells (%) 42.3 (12.4) 46.9 (9.8) 45.2 (7.6) NS NS NS
CD8+ cells (%) 21.6 (10.2) 20.6 (6.4) 19.6 (5.9) NS NS NS
CD19+ cells (%) 13.8 (7.4) 10.9 (7.4) 11.7 (4.1) NS NS NS
CD3+ and HLADR+ cells (%) 13.6 (14.3) 9.4 (7.8) 3.0 (2.3) p,0.01 p,0.01 NS
CD3+ and CD69+ cells (%) 1.5 (1.0) 1.2 (0.9) 1.0 (0.8) NS NS NS
Values are mean (SD).
The samples were measured by flow cytometry and lymphocytes were identified on the basis of their scatter properties.
aPM, active polymyositis; iPM, inactive polymyositis.
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Figure 1 Expression of intracellular
interferon c (IFNc) (panel A) and
interleukin 4 (IL4) (panel B) in stimulated
peripheral T helper (Th) and T cytotoxic
(Tc) cells of patients with
dermatomyositis (DM) and polymyositis
(PM). The samples were measured by
flow cytometry, and lymphocytes were
identified on their scatter properties and
CD4/CD8 positivities.
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The calculated Th/Th2 frequencies were significantly lower
in active dermatomyositis and higher in inactive disease than
in the controls (fig 2).
Intracellular cytokine expression in peripheral
lymphocytes of patients with polymyositis
The frequency of IFNc and IL4 positive Th and Tc cells did not
differ significantly compared with the healthy controls (fig 1A
and 1B). Though the percentages of IL10 positive Th and Tc
lymphocytes—independently of disease activity—were
higher in the patients than in the controls, these differences
were not significant (data are not shown).
Levels of soluble cytokines in serum of patients with
dermatomyositis and polymyositis
Besides the intracellular levels of cytokines we determined
the cytokine patterns in the sera of patients with polymyositis
and dermatomyositis using commercially available ELISA
systems. Probably because of the high degree of individual
variation and the low cytokine levels, hardly any significant
differences could be observed between patients and controls.
In the case of dermatomyositis and polymyositis, indepen-
dently of disease activity the concentrations of IFNc, IL4, and
IL10 were non-significantly raised compared with the
controls (data not shown).
DISCUSSION
This study was undertaken to gain further insight into the
pathogenesis of idiopathic inflammatory myopathies. The
most important finding in our work was the pronounced
difference in the frequency of the peripheral blood lympho-
cyte subsets and also in the intracellular cytokine content of
these cells between patients with active and inactive
polymyositis or dermatomyositis.
In active dermatomyositis we detected not only a sig-
nificantly decreased CD3+ and CD8+ T lymphocyte frequency
but also an increased CD19+ B lymphocyte frequency. The
percentage of activated T cells (CD3+/HLADR+) was signifi-
cantly increased in both dermatomyositis and polymyositis,
but in active polymyositis no other alterations in the
frequency of peripheral blood lymphocytes were detected.
In inactive dermatomyositis these deviations in the lympho-
cyte subsets disappeared and the frequencies of the CD3+,
CD8+, and CD19+ cells became normal, while that of the
activated T lymphocytes was persistently high. In inactive
polymyositis the number of the activated T cells remained
increased as well, without any other alteration in comparison
with with the control population. Iannone et al also studied
the peripheral blood mononuclear cell subsets in patients
with polymyositis and dermatomyositis and, in agreement
with our findings, they detected a normal percentage of total
CD3+/CD8+ cells in polymyositis, while in dermatomyositis
they found a significantly lower proportion CD3+/CD8+ cells
than in controls.19 They also showed that the number of
activated T cells was increased in both polymyositis and
dermatomyositis, although for the detection of activated
T cells they used the CD3+/CD25+ double positive staining,
while we used the CD3+/HLADR+ double positive staining.
Concerning the frequency of B lymphocytes, our results also
show good correlation with published data. In adults with
idiopathic inflammatory myopathies, an increase in the
proportion of B cells in patients with dermatomyositis has
been reported, and an increased frequency of B cells was also
detected in new onset, untreated patients with juvenile
dermatomyositis.20 21 Eisenstein and colleagues observed that
the increased percentage of peripheral blood B cells normal-
ised in children with improving juvenile dermatomyositis,
and this change correlated with changes in disease activity.22
The intracellular cytokine content of the peripheral blood
lymphocytes also showed striking differences between
patients with dermatomyositis and polymyositis. In active
dermatomyositis an altered Th1 and Tc1 lymphocyte fre-
quency was observed, as the percentage of IFNc containing
CD4+ and CD8+ T lymphocytes was significantly decreased
compared with the control population. This prominent
change disappeared in the inactive disease state. On the
other hand in active dermatomyositis a marked increase in
the frequency of CD4+/IL4+ cells was observed, while in
inactive dermatomyositis these changes disappeared and we
detected a decrease in the IL4+/CD4+ cell number compared
with the controls. The frequency of IL4 producing cytotoxic T
lymphocytes was not different between patients and controls.
Studies of lupus-prone mice and humans indicate that
immune abnormalities may be more closely associated with
changes in the frequency of type 2:type 1 cytokine secreting
cells, than with changes in the absolute number of cells
producing any single cytokine.23 For this reason we calculated
the frequency of IL4/IFNc secreting cells. While in active
dermatomyositis a significantly increased Th2/Th1 frequency
was detected, in inactive disease a decrease in Th2/Th1
frequency was found compared with the control population.
Such alterations were not detected in polymyositis.
We also studied the number of IL10 producing Th and Tc
cells. In dermatomyositis and polymyositis we observed an
increase in the percentage of IL10 secreting cells, although
this was significant only in inactive dermatomyositis. The
reason for this discrepancy between the numbers of IL4 and
IL10 producing T cells may be that IL10 is not a pure type 2
cytokine. IL10 is produced by both Th1 and Th2 lymphocytes
and is an important immunoregulatory cytokine. IL10 has the
ability to downregulate several major functions of Th1 cells
and macrophages and can also control the Th2 mediated
inflammatory processes. We detected higher levels of IL10
secreting T cells in dermatomyositis than in polymyositis, but
the difference was not so marked between the two diseases
as was observed in the number of IL4+ or IFNc+ cells.
Lundberg and colleagues carried out indirect immunohis-
tochemistry studies of muscle tissue sections with a panel of 16
different cytokine specific monoclonal antibodies in 15
untreated patients with polymyositis, dermatomyositis, and
inclusion body myositis.17 They concluded that the cytokine
expression in muscle tissue of patients with inflammatory
myopathy is dominated by IL1a, IL1b, and TGFb1–3. INFc
stainingwas detected in six of 15 patients, IL10was observed in
five patients, but IL4 was absent in all patients and the authors
assumed that local release of T cell derived cytokines may
not be a requirement for tissue injury in the inflammatory
myopathies. There did not appear to be a qualitative difference
in cytokine expression patterns in polymyositis, dermatomyo-
sitis, or inclusion bodymyositis. These results do not contradict
our findings, as in autoimmune diseases the cytokine content
of lymphocytes is not necessarily the same in the peripheral
0.3
0
IL4+ and CD4+ cells/IFNγ+ and CD4+ cells
p = 0.03
Active DM
Inactive DM
Control
Active PM
Inactive PM
p < 0.01
p < 0.01
Figure 2 Calculated Th2/Th1 frequency (Th2: IL4+/CD4+; Th1:
IFNc+/CD4+) in active and inactive polymyositis (PM) and
dermatomyositis (DM). IFN, interferon; IL, interleukin; Th, T helper cell.
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blood and in the affected tissues. It is usually accepted that
thyroid autoimmunity is an autoimmune disease mediated by
Th1 cells, but recent results show a major difference in the
balance of Th1 and Th2 cytokines secreted by cultures of
thyroid and peripheral blood lymphocytes.24
To study the cytokine content of the peripheral blood
mononuclear cells Hagiwara and colleagues used the ELIspot
technique and showed that in dermatomyositis patients with
active disease had significantly fewer peripheral blood
mononuclear cells spontaneously secreting IFNc than normal
controls.9 Moreover they showed that subjects with active
dermatomyositis had fewer cells secreting IFNc than patients
with inactive disease. Their results are consistent with our
findings in the case of dermatomyositis, as they also detected
an altered type 1 cytokine pattern. They did not investigate
the number of IL4 containing cells but detected the frequency
IL6 producing cells. They showed a modest but statistically
significant increase in the number of cells secreting IL6 in
patients with dermatomyositis. They also found an altered
type 2/type 1 cytokine frequency in dermatomyositis, similar
to our results, but they counted this frequency from the IL10/
IFNc rate. Instead of IL10 we used IL4 in our calculation, as
type 1 T cells also produce IL10. In the case of polymyositis
our results are in contrast to the findings of Hagiwara and
colleagues, as they found that the number of cells producing
IFNc was also decreased in polymyositis, and patients with
polymyositis showed an increase in IL10 (type 2) production
and a decrease in IFNc (type 1) production. On the other
hand, they also found differences between the cytokine
production of the peripheral blood mononuclear cells of
patients with dermatomyositis and polymyositis. They
showed that dermatomyositis can be distinguished from
the other myopathies by the significantly reduced frequency
of IL2 (type 1) producing, and the increased frequency of IL6
(type 2) producing, peripheral blood mononuclear cells when
compared with other myopathies and normal controls. The
reason for the partial discrepancy between their results and
ours may be that we used different methods for cytokine
determinations.
Serum levels of cytokines were not significantly different
between dermatomyositis, polymyositis, and controls and did
not correlate with results of the intracellular cytokine
staining. This is not surprising, as serum cytokine levels
cannot be used to determine the number of cells secreting
type 1 or type 2 cytokines in vivo owing to their short serum
half life, rapid uptake, utilisation, presence of blocking
factors in the serum, and other sources of production.25–27
Kikuchi and colleagues showed that the percentage of
activated B cells (RP105) in the peripheral blood of patients
with polymyositis was low; in contrast, patients with
dermatomyositis showed an increase in the RP105 negative
B cell populations.5 They concluded that B cell activation in
dermatomyositis may be pathogenically different from that
in polymyositis, and we believe that this B cell activation may
be the result of the increased Th2:Th1 frequency observed in
our study.
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